Tech Company Financing Transactions
InProTher Funding Round
European Innovation Council Fund and private investors participated in a $6.4 million Seed venture round for InProTher. The round was announced on 5/24/2023.
Transaction Overview
Company Name
Announced On
5/24/2023
Transaction Type
Venture Equity
Amount
$6,438,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumors, into clinical development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Novo Nordisk Bioinnovation Institute Ole Maaløes Vej 3
Copenhagen, 2200
DK
Copenhagen, 2200
DK
Phone
Website
Email Address
Overview
InProTher is developing first-in-class immunotherapies against cancer and has pre-clinical proof of concept for broad and curative cancer therapy. Treated animals eliminate their tumors and become resistant to challenge from administered cancer cells. A combination with immune checkpoint inhibitors makes the effect complete in animal models. InProTher's research is based upon research by Associate Professor Peter Johannes Holst and colleagues and international collaborators.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jordi Naval
Browse more venture capital transactions:
Prev: 5/24/2023: Artelon venture capital transaction
Next: 5/24/2023: OpenFin venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs